Neostigmine is a synthetic, quaternary ammonium carbamate derivative that acts as a reversible acetylcholinesterase inhibitor. It prevents the breakdown of acetylcholine at cholinergic synapses, leading to increased cholinergic activity. In the Indian context, the 15mg tablet formulation is primarily used for the symptomatic treatment of myasthenia gravis. It is a critical drug for managing this chronic autoimmune neuromuscular disorder, improving muscle strength by enhancing neuromuscular transmission.
Adult: Myasthenia Gravis: Initial: 15 mg orally every 3-4 hours. Maintenance: Highly individualized, typically 15 to 30 mg repeated as needed. Total daily dose ranges from 75 mg to 300 mg, divided into multiple doses (e.g., 5-6 times daily).
Note: Administer orally with food or milk to reduce gastrointestinal side effects. The tablet should be swallowed whole with a glass of water. Dosing schedule must be strictly adhered to, often timed before periods of anticipated muscle use (e.g., before meals to aid chewing/swallowing). Do not crush or chew.
Neostigmine competitively and reversibly inhibits the enzyme acetylcholinesterase at postsynaptic cholinergic junctions (muscarinic and nicotinic). This inhibition prevents the hydrolysis of acetylcholine, leading to its accumulation in the synaptic cleft. The increased concentration and prolonged action of acetylcholine enhance cholinergic transmission at neuromuscular junctions, autonomic ganglia, and parasympathetic effector sites.
Pregnancy: Category C (US FDA). Use only if potential benefit justifies potential risk to the fetus. May cause uterine irritability. Dose requirements may change during pregnancy and postpartum. Should be managed by a specialist.
Driving: May cause blurred vision, dizziness, or muscle weakness. Patients should be cautioned not to drive or operate machinery until they know how the medication affects them, especially during dose titration.
| Atropine / Other Anticholinergics | Antagonizes muscarinic side effects (e.g., bradycardia, secretions) but may mask early signs of overdose. Can be used therapeutically to manage side effects. | Major |
| Succinylcholine | Neostigmine potentiates and prolongs the Phase I depolarizing block of succinylcholine, leading to prolonged apnea. Contraindicated concurrently. | Contraindicated |
| Non-depolarizing Neuromuscular Blockers (e.g., Rocuronium, Vecuronium) | Neostigmine is used to reverse their effects. Timing is critical. | Major |
| Beta-blockers (e.g., Propranolol) | Additive bradycardia and possible heart block. | Major |
| Aminoglycosides (e.g., Gentamicin), Polymyxins, Clindamycin | May antagonize the effects of neostigmine at the neuromuscular junction, worsening myasthenia symptoms. | Major |
| Magnesium Sulfate | Antagonizes the effects of neostigmine, reducing efficacy in myasthenia gravis. | Major |
| Quinidine, Procainamide | May reverse the anticholinesterase effect, worsening myasthenia. | Major |
| Corticosteroids (e.g., Prednisolone) | Initial worsening of myasthenia may occur when starting steroids, requiring careful neostigmine dose adjustment. | Moderate |